<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02885441</url>
  </required_header>
  <id_info>
    <org_study_id>22/52/1663</org_study_id>
    <nct_id>NCT02885441</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Pancreatitis With Ketorolac</brief_title>
  <official_title>Treatment of Acute Pancreatitis With Ketorolac</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ilam University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ilam University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with acute pancreatitis will be randomly assigned in either study group to receive&#xD;
      oral (injection) Ketorolac or the control group. In patients who cannot tolerate oral&#xD;
      medications, ketorolac injection will be used.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute pancreatitis will be randomly assigned in either study group or control&#xD;
      group.&#xD;
&#xD;
        -  The study group will receive injection or oral Ketorolac.&#xD;
&#xD;
        -  The control group will receive standard medical treatment.&#xD;
&#xD;
      Ketorolac is administrated three times daily by mouth or injection starting from the time of&#xD;
      admission for the first three days of hospitalization (72 hours).&#xD;
&#xD;
      Hs-CRP will be measured in admission in addition to standard laboratory tests.It will be done&#xD;
      every day for up to 5 days, after the administration of study drug or till the time of&#xD;
      discharge whichever occurs earlier. Patients will follow up for organ failure involvement and&#xD;
      duration of hospitalization. The study will continue to gather clinical follow up information&#xD;
      up to four months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Actual">February 1, 2019</completion_date>
  <primary_completion_date type="Actual">February 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in C-Reactive Protein (CRP)</measure>
    <time_frame>baseline to Day 5</time_frame>
    <description>baseline to Day 5</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Organ Failure During Hospitalization</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
    <description>30 days or until dismissal date whichever occurs earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number Of Subjects With New Onset Pancreatic Necrosis During Hospitalization</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
    <description>30 days or until dismissal date whichever occurs earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
    <description>30 days or until dismissal date whichever occurs earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
    <description>30 days or until dismissal date whichever occurs earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of beginning and tolerance to nutrition</measure>
    <time_frame>30 days or until dismissal date whichever occurs earlier</time_frame>
    <description>30 days or until dismissal date whichever occurs earlier</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac,10 mg, 3 times daily from time of enrollment until 72 hours from enrollment for up to a maximum of 9 doses, along with the standard medical treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The standard medical treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>Ketorolac, 10 mg, 3 times daily from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Predicted Severe Acute Pancreatitis&#xD;
&#xD;
          2. Enrollment within 72 hours of diagnosis&#xD;
&#xD;
          3. Obtaining informed consent&#xD;
&#xD;
          4. Age &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Heart disease, Hypertension&#xD;
&#xD;
          2. Hemorrhagic diathesis, Incomplete hemostasis, High risk of bleeding&#xD;
&#xD;
          3. Lactating women&#xD;
&#xD;
          4. Pregnancy&#xD;
&#xD;
          5. Advanced renal disease&#xD;
&#xD;
          6. Hypersensitivity to ketorolac, aspirin, other NSAIDs&#xD;
&#xD;
          7. Concurrent use with aspirin, other NSAIDs, probenecid, or pentoxifylline&#xD;
&#xD;
          8. Active or history of peptic ulcer disease&#xD;
&#xD;
          9. Recent or history of GI bleeding or perforation&#xD;
&#xD;
         10. Inflammatory bowel disease&#xD;
&#xD;
         11. Severe hepatic impairment or active hepatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaahin Shahbazi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ilam University of Medical Scienvc</name>
      <address>
        <city>Ilam</city>
        <zip>6939177143</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 23, 2016</study_first_submitted>
  <study_first_submitted_qc>August 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2016</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ilam University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Vahdat Shariatpanahi</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

